Ken Griffin Amicus Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$9.55 - $12.09 $87,860 - $111,228	-9,200 Reduced 19.29%	38,500 $411,000
Q2 2024 Aug 14, 2024	BUY	$9.04 - $11.75 $242,271 - $314,900	26,800 Added 128.23%	47,700 $473,000
Q1 2024 May 15, 2024	SELL	$11.43 - $14.24 $404,622 - $504,096	-35,400 Reduced 62.88%	20,900 $246,000
Q4 2023 Feb 14, 2024	SELL	$9.97 - $14.52 $79,760 - $116,160	-8,000 Reduced 12.44%	56,300 $798,000
Q3 2023 Nov 14, 2023	BUY	$11.78 - $13.86 $208,506 - $245,322	17,700 Added 37.98%	64,300 $781,000
Q2 2023 Aug 14, 2023	BUY	$10.72 - $13.3 $55,744 - $69,160	5,200 Added 12.56%	46,600 $585,000
Q1 2023 May 15, 2023	SELL	$10.91 - $13.54 $172,378 - $213,932	-15,800 Reduced 27.62%	41,400 $459,000
Q4 2022 Feb 14, 2023	BUY	$9.89 - $12.7 $286,810 - $368,300	29,000 Added 102.84%	57,200 $698,000
Q3 2022 Nov 14, 2022	BUY	$9.82 - $12.75 $19,640 - $25,500	2,000 Added 7.63%	28,200 $294,000

313

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.71B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.